You are here: Industry Insights > Sanofi

News List

Sanofi and Alynylam rejig sees global rights switch-up pharmafile
January 09, 2018
The Sanofi-Alynylam alliance has been in place since 2014, with the latest development seeing the two companies each take their own commercialisation lead on patisiran and fitusiran, respectively.
Sanofi Gains Rights to Hemophilia Drug in Restructured Deal With Alnylam biospace
January 09, 2018
Alnylam the leading RNAi therapeutics company, and Sanofi announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic dis
2 Underappreciated Biotech Stocks to Buy in 2018 biospace
January 03, 2018
George Budwell with The Motley Fool defines value stocks as having solid fundamentals but lower valuations than their peers. Over time, these stocks tend to outperform growth stocks.
Sanofi, Alnylam file hATTR amyloidosis therapy in the EU pharmatimes
December 21, 2017
Sanofi Genzyme and Alnylam Pharmaceuticals have filed marketing applications for patisiran with the European Medicines Agency
Sanofi/Regeneron’s ‘breakthrough’ PD-1 hits positive notes in skin cancer fiercebiotech
December 14, 2017
It may be way back in the race for market share, but Sanofi and Regeneron touted new topline data for their midstage checkpoint inhibitor in a certain form of skin cancer this morning.
Sanofi sees pipeline fruition in 2018 pharmafile
December 14, 2017
In news that Sanofi will no doubt be hoping should divert attention away from the Dengvaxia scandal, the company revealed that it expects to take a number of projects to Phase 3 and to file for regulatory approval in 2018.
FDA approves Sanofi's Admelog biospectrumasia
December 14, 2017
Admelog (insulin lispro injection) 100 Units/mL will be available in U.S. in vial and SoloStar pen
Sanofi issues US-wide recall for arthritis product, after adverse events pharmafile
December 13, 2017
Sanofi has announced a recall of 12,380 syringes of its Synvisc-One product for the treatment of osteoarthritis, after it was noted that a particular batch was associated with unusually high levels of adverse events.
Sanofi's Bad End-of-the-Year Continues With Axing of Its C. Diff Drug biospace
December 05, 2017
Sanofi terminated an experimental Clostridium difficile vaccine after an Independent Data Monitoring Committee concluded the Phase III trial was unlikely to hit its endpoints.
Sanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow biospace
December 01, 2017
Sanofi expects to take a nearly $120 million hit after a long-term study showed use of its dengue vaccine Dengvaxia could worsen the effects of the mosquito-borne illness in people who had previously not been exposed to the virus.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page